{"id":"acetylsalicylic-acid-clopidogrel-acenocoumarol","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding/hemorrhage"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Bruising"}]},"_chembl":{"chemblId":"CHEMBL397420","moleculeType":"Small molecule","molecularWeight":"353.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetylsalicylic acid irreversibly inhibits cyclooxygenase and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-induced platelet activation. Acenocoumarol is a vitamin K antagonist that reduces synthesis of factors II, VII, IX, and X. Together, they provide dual antiplatelet and anticoagulant effects for intensive thromboprophylaxis.","oneSentence":"This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: acetylsalicylic acid and clopidogrel block platelet aggregation, while acenocoumarol inhibits vitamin K-dependent clotting factors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:08.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"High-risk thrombotic conditions requiring intensive anticoagulation and antiplatelet therapy"},{"name":"Acute coronary syndrome with indication for anticoagulation"}]},"trialDetails":[{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT01642134","phase":"PHASE4","title":"Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI","status":"COMPLETED","sponsor":"Andres Iñiguez Romo, MD, PhD","startDate":"2013-04","conditions":"Aortic Valve Stenosis, Stroke","enrollment":124},{"nctId":"NCT01141153","phase":"PHASE4","title":"Anticoagulation in Stent Intervention","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2010-06","conditions":"Atrial Fibrillation, Stroke","enrollment":304},{"nctId":"NCT02309970","phase":"","title":"Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2014-12","conditions":"Ischemic Stroke","enrollment":90},{"nctId":"NCT01020656","phase":"","title":"Anticoagulant and Antiplatelet Agents in Patients Undergoing Vitreoretinal Surgery","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2009-01","conditions":"Retinal Detachment","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Acetylsalicylic Acid + clopidogrel + acenocoumarol","genericName":"Acetylsalicylic Acid + clopidogrel + acenocoumarol","companyName":"Hospital Universitari Vall d'Hebron Research Institute","companyId":"hospital-universitari-vall-d-hebron-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: acetylsalicylic acid and clopidogrel block platelet aggregation, while acenocoumarol inhibits vitamin K-dependent clotting factors. Used for High-risk thrombotic conditions requiring intensive anticoagulation and antiplatelet therapy, Acute coronary syndrome with indication for anticoagulation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}